The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Small-Molecule NOX Inhibitors: ROS-Generating NADPH Oxidases as Therapeutic Targets
Open accessAbstract
NOX NADPH oxidases are electron-transporting membrane enzymes whose primary function is the generation of reactive oxygen species (ROS). ROS produced by NOX enzymes show a variety of biologic functions, such as microbial killing, blood pressure regulation, and otoconia formation. Strong evidence suggests that NOX enzymes are major contributors to oxidative damage in pathologic conditions. Blocking the undesirable actions of NOX enzymes, therefore, is a therapeutic strategy for treating oxidative stress-related pathologies, such as ischemia/reperfusion tissue injury, and neurodegenerative and metabolic diseases. Most currently available NOX inhibitors have low selectivity, potency, and bioavailability, precluding a pharmacologic demonstration of NOX as therapeutic targets in vivo. This review has two main purposes. First, we describe a systematic approach that we believe should be followed in the search for truly selective NOX inhibitors. Second, we present a critical review of small-molecule NOX inhibitors described over the last two decades, including recently published patents from the pharmaceutical industry. Structures, activities, and in vitro/in vivo specificity of these NOX inhibitors are discussed. We conclude that NOX inhibition is a pertinent and promising novel pharmacologic concept, but that major efforts will be necessary to develop specific NOX inhibitors suited for clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989
Self-citationMicroglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 1×
“…through inhibition of geranylgeranylation of Rac (17, 71), nebivolol (78), mycophenolate by decreasing NOX expression (54, 61), dextromethorphan, and related opioid compounds, which protect neurons by inhibiting microglial activation through a NOX2-dependent mechanism (12, 64, 121, 124).”
Lassègue, B., Sorescu, D., Szöcs, K., Yin, Q., Akers, M., Zhang, Y., Grant, S. L., Lambeth, J. D., & Griendling, K. K. (2001) · Circulation Research · doi:10.1161/hh0901.090299 · Cited by 839
Self-citationNOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation
Serrander, L., Cartier, L., Bedard, K., Banfi, B., Lardy, B., Plastre, O., Sienkiewicz, A., Fórró, L., Schlegel, W., & Krause, K.-H. (2007) · Biochemical Journal · doi:10.1042/bj20061903 · Cited by 627
Self-citationCross, A. R., & Jones, O. T. G. (1986) · Biochemical Journal · doi:10.1042/bj2370111 · Cited by 551
Measurement of Reactive Oxygen Species in Cardiovascular Studies
Dikalov, S., Griendling, K. K., & Harrison, D. G. (2007) · Hypertension · doi:10.1161/01.hyp.0000258594.87211.6b · Cited by 532 · cited 2×
“The advantages and disadvantages of the techniques used for the detection of ROS generation were recently reviewed (27, 89).”
The NADPH oxidase of professional phagocytes—prototype of the NOX electron transport chain systems
Cross, A. R., & Segal, A. W. (2004) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2004.03.008 · Cited by 489
An NADPH oxidase superoxide-generating system in the rabbit aorta
Pagano, P. J., Ito, Y., Tornheim, K., Gallop, P. M., Tauber, A. I., & Cohen, R. A. (1995) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1995.268.6.h2274 · Cited by 302
TENFREYHAUS, H., HUNTGEBURTH, M., WINGLER, K., SCHNITKER, J., BAUMER, A., VANTLER, M., BEKHITE, M., WARTENBERG, M., SAUER, H., & ROSENKRANZ, S. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.01.022 · Cited by 259 · cited 2×
“At 10 m M , this compound inhibited oxidized low-density lipoprotein–induced ROS formation in endothelial cells and platelet-derived growth factor–stimulated ROS generation in vascular smooth muscle (98, 103).”
InfluentialNox enzymes as novel targets for drug development
Lambeth, J. D., Krause, K.-H., & Clark, R. A. (2008) · Seminars in Immunopathology · doi:10.1007/s00281-008-0123-6 · Cited by 212
Self-citation
Cited by
Cysteine-Mediated Redox Signaling: Chemistry, Biology, and Tools for Discovery
Paulsen, C. E., & Carroll, K. S. (2013) · Chemical Reviews · doi:10.1021/cr300163e · Cited by 1,278
Cellular death, reactive oxygen species (ROS) and diabetic complications
Volpe, C. M. O., Villar-Delfino, P. H., dos Anjos, P. M. F., & Nogueira-Machado, J. A. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0135-z · Cited by 1,166
NADPH oxidases: An overview from structure to innate immunity-associated pathologies
Panday, A., Sahoo, M. K., Osorio, D., & Batra, S. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2014.89 · Cited by 944
Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets
Drummond, G. R., Selemidis, S., Griendling, K. K., & Sobey, C. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3403 · Cited by 899
Evolution of nadph oxidase inhibitors: Selectivity and mechanisms for target engagement
Altenhöfer, S., Radermacher, K. A., Kleikers, P. W. M., Wingler, K., & Schmidt, H. H. H. W. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5814 · Cited by 521
Rochette, L., Lorin, J., Zeller, M., Guilland, J.-C., Lorgis, L., Cottin, Y., & Vergely, C. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.004 · Cited by 456
Neuroprotective strategies involving ROS in Alzheimer disease
Dumont, M., & Beal, M. F. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.11.026 · Cited by 402
Jaeschke, H., & Woolbright, B. L. (2012) · Transplantation Reviews · doi:10.1016/j.trre.2011.10.006 · Cited by 292
New Insights on NOX Enzymes in the Central Nervous System
Nayernia, Z., Jaquet, V., & Krause, K.-H. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5703 · Cited by 279
Montezano, A. C., & Touyz, R. M. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5302 · Cited by 270
NADPH oxidases in cardiovascular disease
Brandes, R. P., Weissmann, N., & Schröder, K. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.04.030 · Cited by 266
Involvement of NOX2 in the Development of Behavioral and Pathologic Alterations in Isolated Rats
Schiavone, S., Sorce, S., Dubois-Dauphin, M., Jaquet, V., Colaianna, M., Zotti, M., Cuomo, V., Trabace, L., & Krause, K.-H. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.033 · Cited by 208
Self-citationDiscovery of GSK2795039, a Novel Small Molecule NADPH Oxidase 2 Inhibitor
Hirano, K., Chen, W. S., Chueng, A. L. W., Dunne, A. A., Seredenina, T., Filippova, A., Ramachandran, S., Bridges, A., Chaudry, L., Pettman, G., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.6202 · Cited by 205
“To date, a number of small molecules have been shown to block ROS production in primary neutrophils or related cell lines and hence reported as NOX inhibitors (3, 31).”
Self-citationGianni, D., Taulet, N., Zhang, H., DerMardirossian, C., Kister, J., Martinez, L., Roush, W. R., Brown, S. J., Bokoch, G. M., & Rosen, H. (2010) · ACS Chemical Biology · doi:10.1021/cb100219n · Cited by 192
Haslund‐Vinding, J., McBean, G., Jaquet, V, & Vilhardt, F. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13425 · Cited by 169
The nox4 inhibitor gkt137831 attenuates hypoxia-induced pulmonary vascular cell proliferation
Green, D. E., Murphy, T. C., Kang, B.-Y., Kleinhenz, J. M., Szyndralewiez, C., Page, P., Sutliff, R. L., & Hart, C. M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0418oc · Cited by 146
Targeting Vascular NADPH Oxidase 1 Blocks Tumor Angiogenesis through a PPARα Mediated Mechanism
Garrido-Urbani, S., Jemelin, S., Deffert, C., Carnesecchi, S., Basset, O., Szyndralewiez, C., Heitz, F., Page, P., Montet, X., Michalik, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014665 · Cited by 143
Self-citationNox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2
Csányi, G., Cifuentes-Pagano, E., Al Ghouleh, I., Ranayhossaini, D. J., Egaña, L., Lopes, L. R., Jackson, H. M., Kelley, E. E., & Pagano, P. J. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.04.025 · Cited by 131
“To date, several potential inhibitors have been identified, yet most of them seem to exhibit low selectivity, potency, and bioavailability, and none to our knowledge selectively inhibits Nox2 [21].”
InfluentialWhich NADPH Oxidase Isoform Is Relevant for Ischemic Stroke? The Case for Nox 2
Kahles, T., & Brandes, R. P. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4721 · Cited by 125
Schilling, T., & Eder, C. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22675 · Cited by 117
Nox1, 2, 4, 5: Counting out oxidative stress
Wingler, K., Hermans, J., Schiffers, P., Moens, A., Paul, M., & Schmidt, H. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01249.x · Cited by 113
Pharmacology and Clinical Drug Candidates in Redox Medicine
Dao, V. T.-V., Casas, A. I., Maghzal, G. J., Seredenina, T., Kaludercic, N., Robledinos-Anton, N., Di Lisa, F., Stocker, R., Ghezzi, P., Jaquet, V., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6430 · Cited by 88
Self-citationThe Quest for Selective Nox Inhibitors and Therapeutics: Challenges, Triumphs and Pitfalls
Cifuentes-Pagano, E., Meijles, D. N., & Pagano, P. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5620 · Cited by 84
Munnamalai, V., Weaver, C. J., Weisheit, C. E., Venkatraman, P., Agim, Z. S., Quinn, M. T., & Suter, D. M. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12734 · Cited by 70
“Apocynin is still widely used as NADPH oxidase inhibitor; however, there is now evidence that it may act as antioxidant and require the presence of myeloperoxidase to function as a NADPH oxidase inhibitor (Heumuller et al. 2008; Jaquet et al. 2009; Wind et al. 2010).”
BackgroundSkin Redox Balance Maintenance: The Need for an Nrf2-Activator Delivery System
Ben-Yehuda Greenwald, M., Ben-Sasson, S., Bianco-Peled, H., & Kohen, R. (2016) · Cosmetics · doi:10.3390/cosmetics3010001 · Cited by 49
A subset of N-substituted phenothiazines inhibits NADPH oxidases
Seredenina, T., Chiriano, G., Filippova, A., Nayernia, Z., Mahiout, Z., Fioraso-Cartier, L., Plastre, O., Scapozza, L., Krause, K.-H., & Jaquet, V. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.023 · Cited by 45
Self-citationCsányi, G., & Pagano, P. J. (2013) · International Journal of Hypertension · doi:10.1155/2013/842827 · Cited by 20
Metadata
- Authors
- Jaquet, V., Scapozza, L., Clark, R. A., Krause, K.-H., & Lambeth, J. D.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2009-10
- Volume
- 11
- Issue
- 10
- Pages
- 2535-2552
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2118583516
- Cited by
- 243
- References
- 12
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.